MORGAN STANLEY EMERGING MARKETS DEBT FUND INC
No enriched coverage for $MSD in the last 7 days.
No SEC Form 4 filings for $MSD in the last 30 days.
Safehold Inc. has filed a prospectus supplement to register the resale of up to 6,105,389 shares of common stock by identified selling stockholders. The company will not receive proceeds from these resales but will cover registration expenses. The filing details current share ownership by MSD EIV Private Vault, LLC and MSD Vault Investments, LLC, and outlines the plan of distribution for these shares.
COPENHAGEN, Denmark, September 25, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has out-licensed its vaccine candidate EVX-B3 to MSD ( tradename of Merck & Co., Inc., Rahway, NJ, USA ) as per the ...
Shareholders are registering shares for resale; no direct impact on MSD's operational prospects.
The licensing deal is unlikely to have immediate material impact on MSD's stock price.
alphai scores every news story that mentions MSD with an AI model for sentiment and relevance, and aggregates insider trades from MORGAN STANLEY EMERGING MARKETS DEBT FUND INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Safehold Inc. has filed a prospectus supplement to register the resale of up to 6,105,389 shares of common stock by identified selling stockholders. The company will not receive proceeds from these resales but will cover registration expenses. The filing details current share ownership by MSD EIV Private Vault, LLC and MSD Vault Investments, LLC, and outlines the plan of distribution for these shares.
2 min readCOPENHAGEN, Denmark, September 25, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has out-licensed its vaccine candidate EVX-B3 to MSD ( tradename of Merck & Co., Inc., Rahway, NJ, USA ) as per the ...
2 min read
